AnaptysBio, Inc.
On April 20, 2026, AnaptysBio completed the spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations business. Learn more First Tracks Bio here.
Anaptys now exclusively manages the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, with a focus on protecting and returning their value to shareholders.
To learn more, visit www.AnaptysBio.com or follow us on LinkedIn.
AWARDS
NEWS
The company’s experimental lgG4 antibody met the primary endpoint in a late-stage study of the rare skin disease. AnaptysBio will submit an application to the FDA by the third quarter of 2024.
It’s been a busy week for research on rare diseases, with several clinical trials from AnaptysBio, Regenxbio, Sangamo and more posting results from ongoing activities.
Shares of AnaptysBio are down more than 16% after imsidolimab failed to meet the endpoint in a Phase II trial assessing its efficacy in hidradenitis suppurativa.
A roundup of last week’s top clinical trial updates and news.
Despite being represented in clinical research, no solutions have been found to circumvent the effects of Alopecia areata. However, there may be hope.
In the interim, Daniel Faga will take the helm as president and CEO after Hamza Suria let go of his executive functions.
It was a busy week for clinical trial announcements. Here’s a look.
AnaptysBio announced that its drug candidate imsidolimab did not demonstrate efficacy in Phase II clinical trials in the treatment of moderate-to-severe acne.
AnaptysBio started the week with some disappointing news for its lead antibody drug imsidolimab.
JOBS
IN THE PRESS